CN111635450B - 鸡蛋花中具有抗糖尿病活性的化合物及其制备方法 - Google Patents

鸡蛋花中具有抗糖尿病活性的化合物及其制备方法 Download PDF

Info

Publication number
CN111635450B
CN111635450B CN202010666396.9A CN202010666396A CN111635450B CN 111635450 B CN111635450 B CN 111635450B CN 202010666396 A CN202010666396 A CN 202010666396A CN 111635450 B CN111635450 B CN 111635450B
Authority
CN
China
Prior art keywords
compound
methanol
gradient elution
compounds
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010666396.9A
Other languages
English (en)
Other versions
CN111635450A (zh
Inventor
谭钦刚
张胜男
赖春华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guilin Medical University
Original Assignee
Guilin Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilin Medical University filed Critical Guilin Medical University
Priority to CN202010666396.9A priority Critical patent/CN111635450B/zh
Publication of CN111635450A publication Critical patent/CN111635450A/zh
Application granted granted Critical
Publication of CN111635450B publication Critical patent/CN111635450B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了鸡蛋花中具有抗糖尿病活性的化合物及其制备方法,所述的化合物有四个,其中化合物1,2,4为新化合物,分别为三萜类化合物lup‑20(29)‑en‑3β‑(1‑(2S‑hydroxypropionate)‑benzoic acid)(1),环烯醚萜类化合物β‑dihydroplumericin A(2),β‑dihydroplumericinic acid(3),吡喃酮类化合物tetrahydro‑4S‑hydroxy‑6β‑heptadecyl‑2H‑pyran‑2‑one(4),并通过光吸收检测法实验进一步研究上述鸡蛋花的化合物1‑4的抗糖尿病效果。结果显示化合物1‑4对α‑葡萄糖甘酶抑制作用强于阳性对照阿卡波糖,特别是化合物1的活性尤为突出;化合物1对PTP1B抑制作用强于阳性对照齐墩果酸,具有较强的活性。本发明从鸡蛋花中发现结构新颖的、具有抗糖尿病活性的化合物,为制备抗糖尿病新药奠定基础。

Description

鸡蛋花中具有抗糖尿病活性的化合物及其制备方法
技术领域
本发明涉及化合物,具体是一种从鸡蛋花中提取分离出来的具有抗糖尿病活性的三萜类、环烯醚萜类、吡喃酮类化合物及其制备方法。
背景技术
鸡蛋花来源为夹竹桃科植物鸡蛋花(Plumeria rubra L.)的干燥的花。花白色黄心,气醇香,味清淡稍苦,为广西道地药材。主要分布于广东、广西、云南、福建等地,广东、广西民间常采其花晒干泡茶饮。鸡蛋花既具有极佳的观赏性,又有许多民族药用作用,如治疗腹泻、痢疾、腹痛、牙痛和耳痛癌症等。据《中国民族志要》记载,其味甘、淡,性凉,有治湿热下痢和解毒、润肺等功效。在墨西哥,鸡蛋花水煎剂被用来治疗和预防糖尿病。近些年研究,鸡蛋花的乙醇水提取物对由链脲佐菌素诱导的糖尿病大鼠抗糖尿病作用。
据文献报道,鸡蛋花抗糖尿病活性多为鸡蛋花各类粗提物的相关报道,关于鸡蛋花具体的活性成分的报道极少。
为了进一步从鸡蛋花中发现新的抗糖尿病活性成分,为新药开发奠定基础,发明人对鸡蛋花进行了化学成分的深入研究。从鸡蛋花中分离提取,并结合抗糖尿病活性筛选,并鉴定了具有抗糖尿病活性的三萜类、环烯醚萜类、吡喃酮类化合物。
发明内容
本发明公开了从鸡蛋花中提取分离出来的具有抗糖尿病活性的三萜类、环烯醚萜类、吡喃酮类化合物,并公开了提取分离方法、结构鉴定,并对其抗糖尿病活性进行了实验。
实现本发明目的的技术方案是:
鸡蛋花中具有抗糖尿病活性的化合物,所述的化合物有四个,其中化合物(1),(2),(4)为新化合物,分别为三萜类化合物2'S-羟基-3'-(3-苯甲酸)-丙酸-20(29)-烯-3β-羽扇豆酯化合物(1),环烯醚萜类化合物β-二氢鸡蛋花素甲化合物A(2),β-二氢鸡蛋花酸化合物(3),吡喃酮类化合物(4R,6S)-2-氢-4-羟基-6-十七烷基-吡喃-2-酮(4),具有下述式所示结构:
Figure 992199DEST_PATH_IMAGE001
2'S-羟基-3'-(3-苯甲酸)-丙酸-20(29)-烯-3β-羽扇豆酯化合物(1)
Figure 988974DEST_PATH_IMAGE002
β-二氢鸡蛋花素甲化合物A(2)
Figure 575813DEST_PATH_IMAGE003
β-二氢鸡蛋花酸化合物(3)
Figure 533405DEST_PATH_IMAGE004
(4R,6S)-2-氢-4-羟基-6-十七烷基-吡喃-2-酮(4)。
上述鸡蛋花中具有抗糖尿病活性的化合物的制备方法,包括如下步骤:
(1)取30 kg鸡蛋花,用95%乙醇没过鸡蛋花表面浸泡4次,每次7天,提取液合并,减压蒸馏除去溶剂,粗提物悬浮于水中,用乙酸乙酯萃取,减压回收溶剂得乙酸乙酯层浸膏1.1 kg;
(2)将乙酸乙酯部位经正相硅胶柱,设置浓度梯度进行洗脱,得十一个流分:I‒XI;
(3)将流份VI经MCI色谱柱层析,甲醇水梯度洗脱,得VI-1至VI-5 五个流份;VI-1流分经ODS反相色谱柱层析,甲醇水梯度洗脱,重结晶得β-二氢鸡蛋花素甲化合物A(2);
将流份V经MCI色谱柱层析,甲醇水梯度洗脱得V-1至V-4 ,再用丙酮洗脱得V-5;
所述V-4流分经正相硅胶柱,然后ODS反相色谱柱层析,甲醇水梯度洗脱得(4R,6S)-2-氢-4-羟基-6-十七烷基-吡喃-2-酮化合物(4);
所述V-5流分减压浓缩沉淀粉末,甲醇洗涤粉末得2'S-羟基-3'-(3-苯甲酸)-丙酸-20(29)-烯-3β-羽扇豆酯化合物(1);
将流分VII经MCI色谱柱层析,甲醇水梯度洗脱,得VII-1至VII-4 四个流份;VII-2流分经LH-20凝胶柱,甲醇洗脱得β-二氢鸡蛋花酸化合物(3)。
步骤(2)所述的正相硅胶柱,洗脱剂采用体积比为,石油醚:丙酮=1:0, 13:1, 4:1, 1:1,至氯仿:甲醇=1:1梯度洗脱。
步骤(3)所述甲醇水梯度洗脱,其中甲醇水的浓度按70%、75%、80%、85%、90%、95%、100%梯度洗脱;
所述的正相硅胶柱,洗脱剂分别采用体积比为石油醚:乙酸乙酯=12:1和石油醚:乙酸乙酯=16:1梯度洗脱。
本发明从鸡蛋花中发现结构新颖的、具有抗糖尿病活性的三萜类、环烯醚萜类、吡喃酮类化合物,为制备抗糖尿病活性新药奠定基础。
附图说明
图1为鸡蛋花化合物1的1H NMR图谱;
图2为鸡蛋花化合物1的13C NMR图谱;
图3为鸡蛋花化合物1的HSQC图谱;
图4为鸡蛋花化合物1的HMBC图谱;
图5为鸡蛋花化合物1的1H-1H COSY图谱;
图6为鸡蛋花化合物1的NEOSY图谱;
图7为鸡蛋花化合物1的Mosher′s法Δδ H S-R 值。
具体实施方式
化合物1结构鉴定,高分辨质谱 (HR-ESI-MS m/z: 617.4229 [M – H], calcdfor C40H57O5 617.4211) 可推测其分子式为C40H58O5,具有12个不饱和度;
Figure 863892DEST_PATH_IMAGE005
+26.77 (c 0.43, DMSO)。IR (KBr) 数据中显示含有OH (υ max 3422 cm‒1),COOH (υ max 1715cm‒1),间位取代苯环(υ max 964, 882, 750 cm‒1)。UV (甲醇) λ max (log ε) 220 (3.46),275 (1.89)。1HNMR (500 MHz, pyridine-d 5) δ H: 0.90 (1H, m, H-1a), 1.62 (1H, m,H-1b), 1.77 (2H, m, H-2), 4.78 (1H, dd, J = 11.7, 4.8 Hz, H-3), 0.78 (1H, m,H-5), 1.35 (1H, m, H-6a), 1.45 (1H, m, H-6b), 1.35 (2H, m, H-7), 1.28 (1H, m,H-9), 1.29 (2H, m, H-11), 1.14 (2H, m, H-12), 1.62 (1H, m, H-13), 0.97 (1H,m, H-15a), 1.67 (1H, m, H-15b), 1.42 (1H, m, H-16a), 1.50 (1H, m, H-16b),1.42 (1H, m, H-18), 2.48 (1H, td, J = 11.0, 5.8 Hz, H-19), 1.41 (2H, m, H-21), 1.26 (1H, m, H-22a) 1.40 (1H, m, H-22b), 0.88 (3H, s, H-23), 0.91 (3H,s, H-24), 0.84 (3H, s, H-25), 1.00 (3H, s, H-26), 0.99 (3H, s, H-27), 0.83(3H, s, H-28), 4.75 (1H, dd, J = 2.4, 1.3 Hz, H-29a), 4.90 (1H, dd, J = 2.4,H-29b), 1.75 (3H, s, H-30), 4.96 (1H, m H-2'), 3.44 (1H, dd, J = 13.8, 5.1Hz, H-3'a), 3.51 (1H, dd, J = 13.8, 7.5 Hz, H-3'b), 8.64 (1H, s, H-5'), 8.38(1H, d, J = 7.7 Hz, H-7'), 7.49 (1H, t, J = 7.6 Hz, H-8'), 7.77 (1H, d, J =7.6 Hz, H-9'); 13CNMR (125 MHz, pyridine-d 5) δ C : 39.0 (t, C-1), 24.5 (t, C-2),82.0 (d, C-3), 38.6 (s, C-4), 56.0 (d, C-5), 18.9 (t, C-6), 34.9 (t, C-7),41.5 (s, C-8), 50.9 (d, C-9), 37.7 (s, C-10), 21.5 (t, C-11), 25.9 (t, C-12),38.7 (d, C-13), 43.5 (s, C-14), 28.2 (t, C-15), 36.2 (t, C-16), 43.7 (s, C-17), 49.0 (d, C-18), 48.7 (d, C-19), 151.5 (s, C-20), 30.6 (t, C-21), 40.7(t, C-22), 28.5 (q, C-23), 17.2 (q, C-24), 16.7 (q, C-25), 16.6 (q, C-26),15.2 (q, C-27), 18.6 (q, C-28),110.4 (t, C-29), 19.9 (q, C-30), 174.9 (s, C-1'), 72.8 (d, C-2'), 41.8 (t, C-3'), 139.3 (s, C-4'), 132.3(d, C-5'), 133.3(s, C-6'), 128.9 (d, C-7'), 129.1 (d, C-8'), 134.9 (d, C-9'), 169.8 (s, C-10')。如图1所示,化合物1的1H NMR数据显示有两个末端双键质子(δ H 4.75, 4.90),和7个角甲基 (δ H 0.83, 0.84, 0.88, 0.91, 0.99, 1.00, 1.75)。如图2和图3所示,13C NMR和HSQC谱中的碳原子类型及相关数据给出双键化学位移在 (δ C 110.4, 151.5) 处,提示化合物1的分子式中含有羽扇豆烷型三萜骨架。1H NMR,13C NMR数据也显示化合物中含有1个间位双取代的苯环 [δ C 128.9, 129.1, 132.3, 133.3, 134.9, 139.3; δ H 7.49 (t, 7.6Hz), 7.77 (d, 7.6 Hz), 8.38 (d, 7.7 Hz), 8.64 (s)],两个羰基 (δ C 169.8, 174.9)信号。如图4所示,HMBC图谱中,H-3(δ H 4.78) 与C-23, 24, 1′ (δ C 28.5, 17.2, 174.9)相关,可知该化合物在羽扇豆烷母核的3位被酯基取代。该化合物与已知化合物lupeol β-phenyl propionate相似,不同之处在于:根据H-2′ (δ H 4.96) 与C-1′, 3′, 4′ (δ C174.9, 41.8, 139.3) 相关,H-3′ (δ H 3.44, 3.51) 与C-1′, 2′, 4′, 5′ (δ C 174.9,72.8, 139.3, 132.3) 相关,以及如图5所示,1H-1H COSY图谱中H-2′(δ H 4.96) 与H-3′(δ H 3.44, 3.51) 相关,说明2′位被羟基取代。而因苯环为间位双取代,根据HMBC图谱中,H-5′(δ H 8.64) 和H-7′(δ H 8.38) 均与C-10′ (δ C 169.8) 相关,证明苯环的6′为羧基。如图6所示,NOESY图谱中,H-3 (δ H 4.78) 与H-5 (δ H 0.78), H-23 (δ H 0.88) 相关,说明3位为β构型。用Mosher′s法确定2′仲醇手性碳的绝对构型。(R)-MTPA 和(S)-MTPA试剂分别对本化合物进行酯化反应,比较(R)-MTPA 和(S)-MTPA酯的1H NMR得到的Δδ H S-R ,如图7所示,根据羟基两侧的Δδ H S-R 的正负来判断仲醇的构型为2′S。综上可以推断该化合物结构鉴定为2'S-羟基-3'-(3-苯甲酸)-丙酸-20(29)-烯-3β-羽扇豆酯化合物,该化合物为新化合物。
化合物2结构鉴定,根据高分辨质谱 (HR-ESI-MS m/z: 329.1001 [M + Na],calcd for C16H18O6Na 329.0996) 可推测其分子式为C16H18O6,有7个不饱和度。
Figure 228357DEST_PATH_IMAGE005
+187.84 (c 0.21, CH3COCH3)。IR (KBr) 数据显示含有OH (υ max 3443 cm‒1),酯基 (υ max 1784, 1267 cm‒1),C=C (υ max 1690 cm‒1)。UV (甲醇) λ max (log ε) 225 (3.29)。1HNMR(400 MHz, CD3COCD3) δ H : 5.73 (1H, d, J = 8.0 Hz, H-1), 7.45(1H, s, H-3), 3.97(1H, dt, J = 2.4, 10.0 Hz, H-5), 6.07 (1H, dd, J = 2.4, 5.6 Hz, H-6), 5.85(1H, dd, J = 6.0, 10.0 Hz, H-7), 3.52 (1H, dd, J = 2.4, 5.6 Hz, H-9), 4.45(1H, s, H-10), 2.70 (1H, m, H-11), 1.78 (2H, m, H-13), 1.11 (3H, t, J = 7.6Hz, H-14), 4.21 (2H, m, H-16), 1.28 (3H, t, J = 7.2Hz, H-17). 13CNMR (100 MHz,CD3COCD3) δ C : 102.4 (d, C-1), 153.1 (d, C-3), 109.7 (s, C-4), 38.8 (d, C-5),141.7 (d, C-6), 127.8 (d, C-7), 106.7 (s, C-8), 54.2 (d, C-9), 87.4 (d, C-10), 49.5 (d, C-11), 176.9 (t, C-12), 23.2 (t, C-13), 12.2 (s, C-14), 166.7(t, C-15), 60.7 (t, C-16), 14.6 (s, C-17)。13C NMR和DEPT数据显示化合物2含有16个碳原子,其中2个甲基 (δ C 14.6, 12.2),2个亚甲基 (δ C 60.7, 23.2),8个次甲基 (δ C153.1, 141.7, 127.8, 102.4, 87.4, 54.2, 49.5, 38.8),4个季碳 (δ C176.9, 166.7,109.7, 106.7),上述数据表明化合物2是一个环烯醚萜类化合物。1H NMR数据和13C NMR数据与化合物β-dihydroplumericin相似,不同的是,该化合物数据中多了一个 (δ C 60.7, δ H4.21) 的亚甲基信号。从HMBC和1H-1H COSY图谱上:HMBC谱中,H-17 (δ H 1.28) 与C-16 (δ C60.7) 相关,H-16 (δ H 4.21) 与C-15, 17 (δ C 166.7, 14.6) 相关;1H-1H COSY图谱中H-16 (δ H 4.21) 与H-17 (δ H 1.28) 相关,证明H-16与H-17直接相连,该乙基与酯基相连。在NOESY图谱中H-5 (δ H 3.97) 与 H-1(δ H 5.73) 和H-9 (δ H 3.52)相关,为β构型。综上,该新化合物鉴定为β-二氢鸡蛋花素甲化合物A。
化合物β-二氢鸡蛋花酸化合物3结构鉴定,根据低分辨质谱ESI-MS m/z: 277 [M– H]. 推测分子式为C14H14O61H NMR (400 MHz, CD3COCD3) δ H:5.72 (1H, d, J = 5.9Hz, H-1),7.44 (1H, s, H-3), 3.94 (1H, dt, J = 9.7, 2.3 Hz, H-5), 5.82 (1H,dd, J = 5.5, 2.2 Hz, H-6), 6.05 (1H, dd, J = 5.5, 2.2 Hz, H-7), 3.50 (1H, dd,J = 9.7, 5.9 Hz, H-9), 4.44 (1H, s, H-10), 2.68 (1H, ddd, J = 8.8, 6.5, 1.1Hz, H-11), 1.09 (3H, t, J = 7.4 Hz, H-14). 13C NMR (100 MHz, CD3COCD3) δ C :102.5 (d, C-1), 153.5 (d, C-3), 106.9 (s, C-4), 39.0 (d, C-5), 127.9 (d, C-6), 141.9 (d, C-7), 109.6 (s, C-8), 54.4 (d, C-9), 87.6 (d, C-10), 49.7 (d,C-11), 177.1 (s, C-12), 23.4 (t, C-13), 12.3 (q, C-14), 167.8 (s, C-15)。鉴定该化合物为β-二氢鸡蛋花酸化合物。
化合物(4R,6S)-2-氢-4-羟基-6-十七烷基-吡喃-2-酮化合物4结构鉴定,根据高分辨质谱 (HR-ESI-MS m/z: 377.3034 [M + Na]+, calcd for C22H42O3Na+ 377.3026) 可推测其分子式为C22H42O3,有2个不饱和度。
Figure 861464DEST_PATH_IMAGE005
+ 9.15 (c 0.32, CH3COCH3)。IR (KBr)数据显示含有OH (υ max 3464 cm‒1),酯基 (υ max 1709 cm‒1),长链烷基 (υ max 2922 cm‒1)。UV(甲醇) λ max (log ε) 214 (2.05)。1H NMR (400 MHz, CD3COCD3) δ H:2.61 (1H, dd, J =17.3, 4.7 Hz, H-3a), 2.44 (1H, ddd, J = 17.3, 3.6, 1.8 Hz, H-3b), 4.28 (1H,m, H-4), 1.90 (1H, m, H-5a), 1.70 (1H, m, H-5b), 4.60 (1H, m, H-6), 1.55 (2H,m, H-7), 1.38 (1H, m, H-8a), 1.45 (1H, m, H-8b), 1.24 (1H, s, H-9~20), 1.24(1H, s, H-21), 1.24 (1H, s, H-22), 0.83 (3H, t, J = 6.7 Hz, H-23). 13C NMR(100 MHz, CD3COCD3) δ C : 170.5 (s, C-2), 39.6 (t, C-3), 63.3 (d, C-4), 36.9(t, C-5), 76.3 (d, C-6), 36.7 (t, C-7), 25.9 (t, C-8), 30.0-30.6 (t, C-9~20),32.8 (t, C-21), 23.5 (t, C-22), 14.5 (q, C-23)。化合物4的1H NMR和13C NMR数据是一个长链吡喃酮类化合物,其6位长侧链均为-(CH2)16CH3,和文献中的3β-hydroxyicosan-1,5β-olide相似,3位被羟基取代。但是根据高分辨质谱可知,该化合物比文献化合物的长侧链多了2个亚甲基,故该新化合物被命名为(4R,6S)-2-氢-4-羟基-6-十七烷基-吡喃-2-酮化合物。
下面结合实验进一步说明鸡蛋花的化合物抗糖尿病效果。α-葡萄糖甘酶和蛋白酪氨酸磷酸酶1B(PTP1B)是治疗糖尿病的重要靶点,抑制α-葡萄糖甘酶和蛋白酪氨酸磷酸酶1B(PTP1B)是治疗糖尿病的重要策略。
使用光检测吸收法测定鸡蛋花中化合物1-4的α-葡萄糖甘酶和蛋白酪氨酸磷酸酶1B(PTP1B)抑制活性。
使用阿卡波糖作为阳性对照的体外测定方案评估鸡蛋花中得单体化合物的α-葡萄糖甘酶抑制活性。把对硝基苯α-D-葡萄糖苷 (PNPG) 作为底物,利用α-葡萄糖苷酶催化水解PNPG产生对硝基酚 (PNP),在405 nm处具有很强的吸收性。一定时间内反应体系用酶标仪监测405 nm处的吸收强度变化,来计算试样对α-葡萄糖苷酶的抑制活性。化合物1-4,其IC50分别为19.45 ± 1.62 μM,56.84 ± 13.98 μM, 62.50 ± 23.55 μM, 135.28 ±19.10 μM,表现出突出的抑制活性,远优于阳性对照阿卡波糖的IC50为363.93 ± 95.43μM,特别是化合物1得活性最为突出。
使用齐墩果酸作为阳性对照的体外测定方案评估鸡蛋花中得化合物1-4的PTP1B抑制活性。把磷酸4-硝基苯酯 (p-NPP) 作为底物,利用PTP1B催化水解p-NPP产生对硝基酚(NPP),在405 nm处具有很强的吸收性。一定时间内反应体系用酶标仪监测405 nm处的吸收强度变化,来计算试样对PTP1B的抑制活性。化合物1表现出突出的抑制活性,其IC50为0.21± 0.00 μM远优于阳性对照阿卡波糖的IC50为2.48 ± 0.22μM。

Claims (2)

1.鸡蛋花中具有抗糖尿病活性的化合物的制备方法,包括如下步骤:
(1)取鸡蛋花,用95%乙醇没过鸡蛋花表面浸泡4次,每次7天,提取液合并,减压蒸馏除去溶剂,粗提物悬浮于水中,用乙酸乙酯萃取,减压回收溶剂得乙酸乙酯层浸膏;
(2)将乙酸乙酯部位经正相硅胶柱,设置浓度梯度进行洗脱,得十一个流分:I-XI;
所述的正相硅胶柱,洗脱剂采用体积比为,石油醚:丙酮=1:0, 13:1, 4:1, 1:1,至氯仿:甲醇=1:1梯度洗脱;
(3)将流份VI经MCI色谱柱层析,甲醇水梯度洗脱,得VI-1至VI-5 五个流份;VI-1流分经ODS反相色谱柱层析,甲醇水梯度洗脱,重结晶得β-二氢鸡蛋花素甲化合物A(2),结构为:
Figure 83652DEST_PATH_IMAGE001
将流份V经MCI色谱柱层析,甲醇水梯度洗脱得V-1至V-4 ,再用丙酮洗脱得V-5;
所述V-4流分经正相硅胶柱,然后ODS反相色谱柱层析,甲醇水梯度洗脱得(4R,6S)-2-氢-4-羟基-6-十七烷基-吡喃-2-酮化合物(4),
结构为:
Figure 882981DEST_PATH_IMAGE002
所述V-5流分减压浓缩沉淀粉末,甲醇洗涤粉末得2'S-羟基-3'-(3-苯甲酸)-丙酸-20(29)-烯-3β-羽扇豆酯化合物(1),结构为:
Figure 970148DEST_PATH_IMAGE003
将流分VII经MCI色谱柱层析,甲醇水梯度洗脱,得VII-1至VII-4 四个流份;VII-2流分经LH-20凝胶柱,甲醇洗脱得β-二氢鸡蛋花酸化合物(3),结构为:
Figure 665572DEST_PATH_IMAGE004
步骤(3)所述甲醇水梯度洗脱,其中甲醇水的浓度按70%、75%、80%、85%、90%、95%、100%梯度洗脱;
所述的正相硅胶柱,洗脱剂分别采用体积比为石油醚:乙酸乙酯=12:1和石油醚:乙酸乙酯=16:1梯度洗脱。
2.根据权利要求1所述的制备方法制得的化合物的用途,其特征在于:用于制备抗糖尿病活性的药物。
CN202010666396.9A 2020-07-13 2020-07-13 鸡蛋花中具有抗糖尿病活性的化合物及其制备方法 Active CN111635450B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010666396.9A CN111635450B (zh) 2020-07-13 2020-07-13 鸡蛋花中具有抗糖尿病活性的化合物及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010666396.9A CN111635450B (zh) 2020-07-13 2020-07-13 鸡蛋花中具有抗糖尿病活性的化合物及其制备方法

Publications (2)

Publication Number Publication Date
CN111635450A CN111635450A (zh) 2020-09-08
CN111635450B true CN111635450B (zh) 2022-05-24

Family

ID=72327106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010666396.9A Active CN111635450B (zh) 2020-07-13 2020-07-13 鸡蛋花中具有抗糖尿病活性的化合物及其制备方法

Country Status (1)

Country Link
CN (1) CN111635450B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105998031A (zh) * 2016-05-30 2016-10-12 中南民族大学 榼藤子酸的应用及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367210B (en) * 2008-11-17 2012-07-01 Univ Nat Taiwan Estrogenic-active compounds and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105998031A (zh) * 2016-05-30 2016-10-12 中南民族大学 榼藤子酸的应用及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
b-Dihidroplumericinic acid from Himatanthus phagedaenicus;Marcia Paranho Veloso等;《Biochemical Systematics and Ecology 》;19991231;第27卷;第670页 *
Confluentic Acid and 2"-O-Methylperlatolic Acid, Monoamine Oxidase B Inhibitors in a Brazilian Plant, Himatanthus sucuuba;Yuichi Endo等;《Chem.Pharm.Bull.》;19941231;第42卷;第1199页图2 *
uber die Struktur von Plumericin, Isoplumericin, P-Dihydroplumericin und der p-Dihydroplumericinsaure;G.Albers-Schonberg等;《HELVETICA CHIMICA ACTA》;19611231;第XLIV卷;第1456页化合物XXIX *

Also Published As

Publication number Publication date
CN111635450A (zh) 2020-09-08

Similar Documents

Publication Publication Date Title
Mishra et al. Euphane triterpenoid and lipid constituents from Butea monosperma
Zhao et al. Cucurbitane-type triterpenoids from the stems and leaves of Momordica charantia
CN109912680B (zh) 一种齐墩果烷型三萜皂苷及其提取分离方法和应用
Huang et al. Studies on cytotoxic pregnane sapogenins from Cynanchum wilfordii
Gu et al. Constituents of Eugenia sandwicensis with potential cancer chemopreventive activity
Chaabi et al. Acylated flavonol pentaglycosides from Baphia nitida leaves
Tchinda et al. Vernoguinosterol and vernoguinoside, trypanocidal stigmastane derivatives from Vernonia guineensis (Asteraceae)
D'Acquarica et al. Isolation and structure elucidation of four new triterpenoid estersaponins from fruits of Pittosporum tobira ait.
Farheen et al. Triterpenoids and triterpenoid saponins from the aerial parts of Fagonia indica Burm
Shim et al. Norditerpenoid alkaloids and other components from the processed tubers of Aconitum carmichaeli
Muhammad et al. Triterpenoids from the leaves of Alphitonia xerocarpus Baill and their biological activity
Li et al. New cucurbitane triterpenoids with cytotoxic activities from Hemsleya penxianensis
Siddiqui et al. Triterpenoidal constituents of the leaves of Carissa carandas
Tchinda et al. Stigmastane derivatives and isovaleryl sucrose esters from Vernonia guineensis (Asteraceae)
CN112300242B (zh) 一种呋甾皂苷类化合物单体的制备方法
Ahmad et al. Steroidal saponins from Asparagus dumosus
Zhu et al. Four new dammarane triterpenoid glycosides from the leaves of Cyclocarya paliurus and their SIRT1 activation activities
CN109796511B (zh) 一种新的环烯醚萜类化合物及其制备方法和医药用途
CN111635450B (zh) 鸡蛋花中具有抗糖尿病活性的化合物及其制备方法
Jiang et al. Cucurbitane-type triterpenoids from the aerial parts of Momordica charantia L.
Ee et al. A new benzophenone from Mesua congestiflora, an inhibitor against human B lymphocyte cancer cell line
Li et al. A new triterpenoid saponin from the leaves and stems of Panax quinquefolium L.
Siddiqui et al. Kanerin and 12, 13-dihydroursolic acid, two new pentacyclic triterpenes from the leaves of Nerium oleander
Musa et al. Campesterol from methanol fraction of brotowali (tinospora crispa) stem bark
Donkwe et al. Oxidative burst inhibitory and cytotoxic activity of constituents of the fruits of Odyendyea gabonensis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant